Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.

Br J Cancer 2016 09 18;115(7):776-83. Epub 2016 Aug 18.

Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.

Background: The impact of an inherited BRCA2 mutation on the prognosis of women with breast cancer has not been well documented. We studied the effects of oestrogen receptor (ER) status, other prognostic factors and treatments on survival in a large cohort of BRCA2 mutation carriers.

Methods: We identified 285 breast cancer patients with a 999del5 BRCA2 mutation and matched them with 570 non-carrier patients. Clinical information was abstracted from patient charts and pathology records and supplemented by evaluation of tumour grade and ER status using archived tissue specimens. Univariate and multivariate hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. The effects of various therapies were studied in patients treated from 1980 to 2012.

Results: Among mutation carriers, positive ER status was associated with higher risk of death than negative ER status (HR=1.94; 95% CI=1.22-3.07, P=0.005). The reverse association was seen for non-carriers (HR=0.71; 95% CI: 0.51-0.97; P=0.03).

Conclusions: Among BRCA2 carriers, ER-positive status is an adverse prognostic factor. BRCA2 carrier status should be known at the time when treatment decisions are made.

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046206PMC
September 2016
38 Reads
4.836 Impact Factor

Publication Analysis

Top Keywords

brca2 mutation
16
breast cancer
12
oestrogen receptor
8
mutation carriers
8
receptor status
8
status
7
brca2
6
mutation
5
supplemented evaluation
4
association non-carriers
4
records supplemented
4
evaluation tumour
4
pathology records
4
grade status
4
p=0005 reverse
4
tissue specimens
4
specimens univariate
4
archived tissue
4
status archived
4
non-carriers hr=071
4

References

(Supplied by CrossRef)

A Arason et al.
Breast Cancer Res 2010

T Byrski et al.
J Clin Oncol 2010

FS Collins et al.
N Engl J Med 2015

B Fisher et al.
N Engl J Med 2002

PJ Goodwin et al.
J Clin Oncol 2012

DF Gudbjartsson et al.
Nat Genet 2015

BA Heemskerk-Gerritsen et al.
Int J Cancer 2015

E Honrado et al.
Mod Pathol 2005

T Huzarski et al.
J Clin Oncol 2013

G Johannesdottir et al.
Cancer Res 1996

JM Lee et al.
Ann Oncol 2014

Similar Publications